Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Hepatitis C × elbasvir-grazoprevir drug combination × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hepatitis C 1 Carcinoma, Hepatocellular 1

Interventions

telaprevir 1 peginterferon alfa-2a 1 hepatitis C immune globulin, human 1 elbasvir-grazoprevir drug combination 1 Ribavirin 1 Introns 1 Immunoglobulin G 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04546802 2020-09-14

HATCHeT

Bayside Health

Phase 3 Withdrawn

Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡